Prostate Cancer Biomarker Predicted Treatment Success

Researchers identified PAM50 luminal B status as a potential predictor for androgen deprivation therapy efficacy.

Updated on Oct. 5, 2026 in Cancer

Bold flat-color editorial illustration of a glass medical specimen vial, symbolizing prostate cancer research and biomarker analysis. — Researchers have identified the PAM50 luminal B biomarker as a predictor of success for androgen deprivation therapy in prostate cancer patients. AI Illustration. Upload story photo >

Live Poll

Should genetic screening be a standard requirement to determine the necessity of cancer therapy?

A study using the NRG/RTOG 0534 SPPORT trial has linked PAM50 luminal B status to improved outcomes in prostate cancer patients receiving androgen deprivation therapy. The findings suggest this biomarker may help clinicians better predict which patients benefit most from specific treatment regimens.

Why it matters

Identifying specific biological subtypes allows for more personalized prostate cancer care. This biomarker approach helps distinguish patients likely to respond well to therapy from those who might not, potentially optimizing treatment choices to avoid unnecessary interventions.

The analysis of 709 prostatectomy samples showed that the luminal B group experienced a 31% absolute benefit in 5-year freedom from progression and a 20% rate of 10-year metastasis-free survival. These outcomes were compared against non-luminal B cohorts.

The players

ASTRO

The American Society for Radiation Oncology is a professional medical society that hosts annual meetings to share advancements in radiation therapy research.

NRG/RTOG 0534 SPPORT trial

This is a large-scale clinical research trial designed to investigate treatment options for prostate cancer patients, specifically focusing on radiation and hormone therapy combinations.

The details

Researchers utilized PAM50 profiling to categorize prostatectomy samples into luminal B or non-luminal B subtypes, noting that luminal B tumors display increased proliferative and androgen receptor signaling. The trial compared treatment pathways including prostate bed radiation alone versus radiation combined with short-term androgen deprivation therapy and pelvic lymph node radiation.

The findings were presented at the ASTRO annual meeting held from September 26 to September 30, 2026.

The Big Picture

This research extends the findings established by the NRG/RTOG 0534 SPPORT trial by integrating molecular subtyping into clinical outcome data. It marks a shift toward utilizing genetic markers to refine treatment protocols previously evaluated solely through traditional clinical metrics.

This research could eventually allow patients and their doctors to tailor prostate cancer treatment plans based on a tumor's specific molecular profile. By identifying who is most likely to benefit from androgen deprivation, patients may avoid the physical side effects of therapies that are unlikely to improve their specific outcome.

The takeaway

Using molecular profiling like PAM50 may transform prostate cancer management by moving away from a one-size-fits-all treatment approach. Patients should discuss with their oncologists whether genetic testing of biopsy or surgical samples is appropriate for their specific case.